Host factors determining the efficacy of hepatitis C treatment

摘要: Combination therapy with pegylated interferon and ribavirin is the standard of care (SOC) for treatment chronic hepatitis C (CHC). Treating CHC SOC may show a sustained virological response (SVR) in approximately 50–70 % genotype 1 patients an SVR 70–90 % 2 patients. The genotype, baseline viral load, kinetics (i.e., rapid virologic early response) can be used as predictors response-guided therapy. Nonetheless, host factors, e.g. age, ethnicity, insulin resistance, genetic variations, also play important roles treated SOC. Recent genome-wide association studies have demonstrated that single-nucleotide polymorphisms near interleukin 28B gene (IL28B) were associated to IL28B contribute during treatment. Asian people favorable polymorphisms. This factor at least partly explain high eradication rate by Asia. direct-acting antivirals (DAAs) increase rates both treatment-naive treatment-experienced Although affect triple first-generation protease inhibitors, pilot potent DAAs might overcome influence Thus, virus infection could simplified future.